Indication
Tauopathy
8 clinical trials
8 products
Clinical trial
Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.Status: Completed, Estimated PCD: 2021-06-30
Product
XPro1595Product
PlaceboClinical trial
Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's DiseaseStatus: Recruiting, Estimated PCD: 2027-04-16
Product
DonanemabProduct
ACI-35.030Clinical trial
A Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects With Early Alzheimer's DiseaseStatus: Completed, Estimated PCD: 2023-09-05
Product
JACI-35.054Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of APNmAb005 in Healthy SubjectsStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Product
APNmAb005Clinical trial
An Open Label Extension of XPro1595 in Patients With Alzheimer's Disease That Have Completed a Phase 1 or Phase 2 Study With XPro1595Status: Recruiting, Estimated PCD: 2026-05-04
Clinical trial
A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Mild Cognitive Impairment (MCI) With Biomarkers of InflammationStatus: Withdrawn, Estimated PCD: 2023-10-26
Clinical trial
Center Without Walls for Imaging Proteinopathies With PET (CW2IP2): Phase I Pilot Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-M503Status: Recruiting, Estimated PCD: 2029-02-01
Product
11C-M503Clinical trial
Center Without Walls for Imaging Proteinopathies With PET (CW2IP2): Phase I Pilot Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15Status: Recruiting, Estimated PCD: 2028-07-31
Product
11C-HY-2-15